(RTTNews) - MiNK Therapeutics, Inc. (INKT), a clinical-stage biopharmaceutical company, Thursday announced that it has received formal notice from Nasdaq confirming its regained compliance with ...
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback